🇺🇸 FDA
Pipeline program

anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy

Surpass

Unknown small_molecule active

Quick answer

anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy for Effect Increased is a Unknown program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
Effect Increased
Phase
Unknown
Modality
small_molecule
Status
active

Clinical trials